Virginia A. Moyer, MD, MPH; on behalf of the U.S. Preventive Services Task Force (*)
Disclaimer: Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
Financial Support: The USPSTF is an independent, voluntary body. The U.S. Congress mandates that the Agency for Healthcare Research and Quality support the operations of the USPSTF.
Potential Conflicts of Interest: The authors declared that their organization's policy regarding management of conflicts of interest was followed in the development of this clinical guideline. Disclosure forms from USPSTF members can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M13-2905.
Requests for Single Reprints: Reprints are available from the USPSTF Web site (www.uspreventiveservicestaskforce.org).
Moyer VA, on behalf of the U.S. Preventive Services Task Force. Screening for Gestational Diabetes Mellitus: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2014;160:414-420. doi: 10.7326/M13-2905
Download citation file:
Published: Ann Intern Med. 2014;160(6):414-420.
Update of the 2008 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for gestational diabetes mellitus (GDM).
The USPSTF reviewed the evidence on the accuracy of screening tests for GDM, the benefits and harms of screening before and after 24 weeks of gestation, and the benefits and harms of treatment in the mother and infant.
This recommendation applies to pregnant women who have not been previously diagnosed with type 1 or 2 diabetes mellitus.
The USPSTF recommends screening for GDM in asymptomatic pregnant women after 24 weeks of gestation. (B recommendation)
The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for GDM in asymptomatic pregnant women before 24 weeks of gestation. (I statement)
Screening for gestational diabetes mellitus: clinical summary of U.S. Preventive Services Task Force recommendation.
GDM = gestational diabetes mellitus.
Appendix Table 1. What the USPSTF Grades Mean and Suggestions for Practice
Appendix Table 2. USPSTF Levels of Certainty Regarding Net Benefit
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Allan R. Glass, M.D.
January 15, 2014
Endocrine Society differs with USPSTF recommendations
I would note that the Endocrine Society has issued a statement (https://www.endocrine.org/news-room/current-press-releases/endocrine-society-recommends-universal-diabetes-testing-at-first-prenatal-visit) in which it takes exception to a USPSTF recommendation regarding screening for gestational diabetes mellitus. Specifically, the Endocrine Society endorses screening at the first prenatal visit (13 weeks or earlier) while USPSTF recommends screening at 24-28 weeks. In addition, the Endocrine Society strongly recommends using a 75 g glucose tolerance test for screening; the USPSTF takes no position on the choice of screening test, although the 50 g glucose challenge is probably most widely used in the U.S.
Cardiology, Endocrine and Metabolism, Diabetes, Guidelines, Coronary Risk Factors.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only